Related Experiment Video
Updated: May 24, 2026
07:48
Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis
Published on: January 7, 2019
Targeted RGD nanoparticles for highly sensitive in vivo integrin receptor imaging
Ren-Yen Lin1, Kasala Dayananda, Ting-Jung Chen
1Department of Biological Science and Technology, National Chiao Tung University, 75 Bo-Ai Street, Hsinchu, 300, Taiwan.
Contrast Media & Molecular Imaging
|February 21, 2012
Summary
New ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles conjugated with RGD peptide show high sensitivity for early tumor detection using magnetic resonance imaging (MRI). These RGD nanoparticles provide remarkable negative contrast, aiding in differentiating cancer cells.
Area of Science:
- Nanotechnology
- Biomedical Imaging
- Materials Science
Background:
- Ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles offer potential as MRI contrast agents.
- Targeted delivery systems are crucial for enhancing the specificity of diagnostic agents.
- Integrin receptors are overexpressed in various cancer types, making them attractive targets.
Purpose of the Study:
- To develop and characterize RGD peptide-conjugated USPIO nanoparticles for targeted MRI.
- To evaluate the efficacy of these nanoparticles in detecting and differentiating cancer cells and tumors.
- To assess the potential of RGD nanoparticles for early-stage tumor diagnosis.
Main Methods:
- Synthesis and size tuning of USPIO nanoparticles (6-13 nm) by controlling stirring rates.
- Coating USPIO nanoparticles with PDA (2-(pyridyldithio)-ethylamine) via Michael addition.
- Conjugation of PDA nanoparticles with RGD peptide for targeted delivery.
- In vitro and in vivo MRI studies on various cell lines (MCF-7, A-549, HT-29, HT-1080) and tumors.
Main Results:
- USPIO nanoparticles (13.1 ± 2.1 nm) exhibited high transversal relaxivity (r₂ = 188 ± 3 m⁻¹s⁻¹) and saturation magnetization (94 emu/g Fe).
- RGD nanoparticles demonstrated target specificity, differentiating integrin receptor expression levels.
- A significant negative contrast (-51.3 ± 6.7%) was achieved in vivo for MCF-7 tumors.
Conclusions:
- RGD-conjugated USPIO nanoparticles serve as effective MRI contrast agents with high sensitivity.
- These nanoparticles show promise for early-stage tumor detection and diagnosis.
- The targeted approach enhances MRI capabilities for cancer imaging.
